ERBB2 and breast cancer: Notably, the Her2-positive breast cancer subtype in TCGA had threefold more APOBEC-driven SGMs than all other subtypes combined (2.9 versus 0.95 SGMs per genome) (Fig. 4B), consistent with earlier studies showing higher APOBEC activity in that subtype (8).